{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T01:28:18Z","timestamp":1767922098159,"version":"3.49.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.vaccine.2023.01.038","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T08:10:48Z","timestamp":1675066248000},"page":"1573-1583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Development of stable HEK293T cell pools expressing CSFV E2 protein: A potential antigen expression platform"],"prefix":"10.1016","volume":"41","author":[{"given":"Yanmin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daoyuan","family":"Na","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiwei","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Song","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8077-3617","authenticated-orcid":false,"given":"Liang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.01.038_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12866-020-1713-2","article-title":"Identification of E2 with improved secretion and immunogenicity against CSFV in piglets","volume":"20","author":"Xu","year":"2020","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.vaccine.2023.01.038_b0010","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/infdis\/jiu648","article-title":"Raising Expectations For Subunit Vaccine","volume":"211","author":"Schiller","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.038_b0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ddtec.2021.02.003","article-title":"Recent advances in CHO cell line development for recombinant protein production","volume":"38","author":"Tihanyi","year":"2021","journal-title":"Drug Discovery Today: Technol"},{"key":"10.1016\/j.vaccine.2023.01.038_b0020","doi-asserted-by":"crossref","first-page":"e106891","DOI":"10.1371\/journal.pone.0106891","article-title":"Generation and efficacy evaluation of recombinant classical swine fever virus E2 glycoprotein expressed in stable transgenic mammalian cell line","volume":"9","author":"Hua","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.01.038_b0025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jbiotec.2016.10.005","article-title":"Enhancing heterologous protein expression and secretion in HEK293 cells by means of combination of CMV promoter and IFN\u03b12 signal peptide","volume":"239","author":"Rom\u00e1n","year":"2016","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2023.01.038_b0030","doi-asserted-by":"crossref","first-page":"e0197656","DOI":"10.1371\/journal.pone.0197656","article-title":"Robotic selection for the rapid development of stable CHO cell lines for HIV vaccine production","volume":"13","author":"O'Rourke","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.01.038_b0035","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.copbio.2009.10.008","article-title":"Expression systems for therapeutic glycoprotein production","volume":"20","author":"Durocher","year":"2009","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.vaccine.2023.01.038_b0040","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0958-1669(00)00127-0","article-title":"Site-specific gene targeting for gene expression in eukaryotes","volume":"11","author":"Gorman","year":"2000","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.vaccine.2023.01.038_b0045","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/bit.22968","article-title":"Generation of stable, high-producing cho cell lines by lentiviral vector-mediated gene transfer in serum-free suspension culture","volume":"108","author":"Oberbek","year":"2011","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2023.01.038_b0050","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jbiotec.2017.06.009","article-title":"Rapid protein production from stable CHO cell pools using plasmid vector and the cumate gene-switch","volume":"255","author":"Poulain","year":"2017","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2023.01.038_b0055","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jbiotec.2015.03.001","article-title":"Rapid recombinant protein production from piggyBac transposon-mediated stable CHO cell pools","volume":"200","author":"Balasubramanian","year":"2015","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2023.01.038_b0060","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/bit.22698","article-title":"High-level recombinant protein production in CHO cells using lentiviral vectors and the cumate gene-switch","volume":"106","author":"Gaillet","year":"2010","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2023.01.038_b0065","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nprot.2009.22","article-title":"Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors","volume":"4","author":"Kutner","year":"2009","journal-title":"Nat Protoc"},{"key":"10.1016\/j.vaccine.2023.01.038_b0070","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1021\/bp0501524","article-title":"Regulation of Recombinant Monoclonal Antibody Production in Chinese Hamster Ovary Cells: A Comparative Study of Gene Copy Number, mRNA Level, and Protein Expression","volume":"22","author":"Jiang","year":"2006","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.vaccine.2023.01.038_b0075","doi-asserted-by":"crossref","first-page":"5953","DOI":"10.1007\/s00253-018-8986-5","article-title":"Efficient mAb production in CHO cells with optimized signal peptide, codon, and UTR","volume":"102","author":"You","year":"2018","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2023.01.038_b0080","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ejcb.2018.06.003","article-title":"A comprehensive review of signal peptides: Structure, roles, and applications","volume":"97","author":"Owji","year":"2018","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.vaccine.2023.01.038_b0085","doi-asserted-by":"crossref","unstructured":"Low KO, Muhammad Mahadi N, Md. Illias R. Optimisation of signal peptide for recombinant protein secretion in bacterial hosts. Appl Microbiol Biotechnol 2013;97:3811-3826.","DOI":"10.1007\/s00253-013-4831-z"},{"key":"10.1016\/j.vaccine.2023.01.038_b0090","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/bit.24776","article-title":"Optimized signal peptides for the development of high expressing CHO cell lines","volume":"110","author":"Kober","year":"2013","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2023.01.038_b0095","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/21655979.2016.1176656","article-title":"Enhanced recombinant factor VII expression in Chinese hamster ovary cells by optimizing signal peptides and fed-batch medium","volume":"7","author":"Peng","year":"2016","journal-title":"Bioengineered"},{"key":"10.1016\/j.vaccine.2023.01.038_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2020.107552","article-title":"Mammalian cell culture for production of recombinant proteins: A review of the critical steps in their biomanufacturing","volume":"43","author":"O\u2019Flaherty","year":"2020","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.vaccine.2023.01.038_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2013.10.025","article-title":"The challenges of classical swine fever control: Modified live and E2 subunit vaccines","volume":"179","author":"Huang","year":"2014","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2023.01.038_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbiotec.2014.01.007","article-title":"Enhancing expression of the classical swine fever virus glycoprotein E2 in yeast and its application to a blocking ELISA","volume":"174","author":"Cheng","year":"2014","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2023.01.038_b0115","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/elsc.201900147","article-title":"Expression of recombinant classical swine fever virus E2 glycoprotein by endogenous Txnip promoter in stable transgenic CHO cells","volume":"20","author":"Feng","year":"2020","journal-title":"Eng Life Sci"},{"key":"10.1016\/j.vaccine.2023.01.038_b0120","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.vaccine.2007.11.014","article-title":"Classical swine fever virus E2 glycoprotein antigen produced in adenovirally transduced PK-15 cells confers complete protection in pigs upon viral challenge","volume":"26","author":"S\u00e1nchez","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.038_b0125","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ymeth.2018.05.013","article-title":"Expression of recombinant proteins in insect and mammalian cells","volume":"147","author":"McKenzie","year":"2018","journal-title":"Methods"},{"key":"10.1016\/j.vaccine.2023.01.038_b0130","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.sbi.2016.06.005","article-title":"Recombinant protein production from stable mammalian cell lines and pools","volume":"38","author":"Hacker","year":"2016","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.vaccine.2023.01.038_b0135","first-page":"669","article-title":"Expression and immunogenicity analysis of classical swine fever virus E2-GM-CSF fusion protein in HEK293T Cells","volume":"49","author":"Zhang","year":"2022","journal-title":"China Animal Husbandry and Veterinary Medicine"},{"key":"10.1016\/j.vaccine.2023.01.038_b0140","doi-asserted-by":"crossref","unstructured":"Aziza P. Manceur, Howard Kim, Vanja Misic, Nadejda Andreev, July Dorion-Thibaudeau, Ste \u0301phane Lanthier, et al. Scalable lentiviral vector production using stable HEK293SF producer cell lines. Hum Gene Ther Method 2017;28:330-339.","DOI":"10.1089\/hgtb.2017.086"},{"key":"10.1016\/j.vaccine.2023.01.038_b0145","doi-asserted-by":"crossref","first-page":"e2000351","DOI":"10.1002\/biot.202000351","article-title":"Comprehensive characterization of dihydrofolate reductase-mediated gene amplification for the establishment of recombinant human embryonic kidney 293 cells producing monoclonal antibodies","volume":"16","author":"Lee","year":"2021","journal-title":"Biotechnol J"},{"key":"10.1016\/j.vaccine.2023.01.038_b0150","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10616-014-9693-4","article-title":"Evaluating the bottlenecks of recombinant IgM production in mammalian cells","volume":"67","author":"Chromikova","year":"2015","journal-title":"Cytotechnology"},{"key":"10.1016\/j.vaccine.2023.01.038_b0155","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1016\/j.vaccine.2019.04.054","article-title":"Semi-perfusion cultures of suspension MDCK cells enable high cell concentrations and efficient influenza A virus production","volume":"37","author":"Bissinger","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.038_b0160","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S1369-703X(03)00180-3","article-title":"TubeSpin satellites: a fast track approach for process development with animal cells using shaking technology","volume":"17","author":"De Jesus","year":"2004","journal-title":"Biochem Eng J"},{"key":"10.1016\/j.vaccine.2023.01.038_b0165","doi-asserted-by":"crossref","first-page":"6953","DOI":"10.1007\/s00253-020-10744-3","article-title":"Investigation into the impact of tyrosine on the product formation and quality attributes of mAbs in rCHO cell cultures","volume":"104","author":"Zhang","year":"2020","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2023.01.038_b0170","doi-asserted-by":"crossref","first-page":"7353","DOI":"10.1016\/j.vaccine.2018.10.030","article-title":"Enhanced protective immunity to CSFV E2 subunit vaccine by using IFN-\u03b3 as immunoadjuvant in weaning piglets","volume":"36","author":"Zhang","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.038_b0175","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0006-291X(02)00566-1","article-title":"Human secretory signal peptide description by hidden Markov model and generation of a strong artificial signal peptide for secreted protein expression","volume":"294","author":"Barash","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.vaccine.2023.01.038_b0180","doi-asserted-by":"crossref","first-page":"1700175","DOI":"10.1002\/biot.201700175","article-title":"Optimized Selection Marker and CHO Host Cell Combinations for Generating High Monoclonal Antibody Producing Cell Lines","volume":"12","author":"Yeo","year":"2017","journal-title":"Biotechnol J"},{"key":"10.1016\/j.vaccine.2023.01.038_b0185","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.eurpolymj.2019.03.009","article-title":"Polymers for subunit vaccine delivery","volume":"114","author":"Nevagi","year":"2019","journal-title":"Eur Polym J"},{"key":"10.1016\/j.vaccine.2023.01.038_b0190","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.3390\/v7072783","article-title":"Structures and functions of pestivirus glycoproteins: not simply surface matters","volume":"7","author":"Wang","year":"2015","journal-title":"Viruses-Basel"},{"key":"10.1016\/j.vaccine.2023.01.038_b0195","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1006\/jmbi.2000.4315","article-title":"Predicting transmembrane protein topology with a hidden markov model: application to complete genomes11Edited by F","volume":"305","author":"Krogh","year":"2001","journal-title":"Cohen J Mol Biol"},{"key":"10.1016\/j.vaccine.2023.01.038_b0200","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0960-9822(02)00482-7","article-title":"Codon usage limitation in the expression of HIV-1 envelope glycoprotein","volume":"6","author":"Haas","year":"1996","journal-title":"Curr Biol"},{"key":"10.1016\/j.vaccine.2023.01.038_b0205","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0166-0934(03)00173-3","article-title":"Effects of codon-optimization on protein expression by the human herpesvirus 6 and 7 U51 open reading frame","volume":"111","author":"Bradel-Tretheway","year":"2003","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2023.01.038_b0210","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1128\/JVI.74.6.2628-2635.2000","article-title":"Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene","volume":"74","author":"Zur Megede","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.01.038_b0215","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12985-017-0898-y","article-title":"Global phylogenetic analysis of contemporary aleutian mink disease viruses (AMDVs)","volume":"14","author":"Ryt-Hansen","year":"2017","journal-title":"Virol"},{"key":"10.1016\/j.vaccine.2023.01.038_b0220","doi-asserted-by":"crossref","first-page":"19771","DOI":"10.1016\/S0021-9258(19)77701-1","article-title":"Importance of the propeptide sequence of human preproparathyroid hormone for signal sequence function","volume":"263","author":"Wiren","year":"1988","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2023.01.038_b0225","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/mol.108.051581","article-title":"The sequence after the signal peptide of the G protein-coupled endothelin B receptor is required for efficient translocon gating at the endoplasmic reticulum membrane","volume":"75","author":"Alken","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.vaccine.2023.01.038_b0230","doi-asserted-by":"crossref","first-page":"2000391","DOI":"10.1002\/biot.202000391","article-title":"Accelerating HIV-1 VLP production using stable High Five insect cell pools","volume":"16","author":"Puente-Massaguer","year":"2021","journal-title":"Biotechnol J"},{"key":"10.1016\/j.vaccine.2023.01.038_b0235","doi-asserted-by":"crossref","first-page":"10469","DOI":"10.1007\/s00253-018-9388-4","article-title":"A new strategy for fed-batch process control of HEK293 cell cultures based on alkali buffer addition monitoring: comparison with O.U.R. dynamic method","volume":"102","author":"Mart\u00ednez-Monge","year":"2018","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2023.01.038_b0240","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.nbt.2021.07.002","article-title":"Fed-batch production assessment of a tetravalent bispecific antibody: A case study on piggyBac stably transfected HEK293 cells","volume":"65","author":"Napoleone","year":"2021","journal-title":"New Biotechnol"},{"key":"10.1016\/j.vaccine.2023.01.038_b0245","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jbiotec.2019.12.017","article-title":"Small-scale bioreactor supports high density HEK293 cell perfusion culture for the production of recombinant Erythropoietin","volume":"309","author":"Schwarz","year":"2020","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2023.01.038_b0250","doi-asserted-by":"crossref","first-page":"6970","DOI":"10.1016\/j.vaccine.2019.05.064","article-title":"Zika virus-like particles (VLPs): Stable cell lines and continuous perfusion processes as a new potential vaccine manufacturing platform","volume":"37","author":"Alvim","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.038_b0255","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1128\/JVI.01824-06","article-title":"N-linked glycosylation status of classical swine fever virus strain Brescia E2 glycoprotein influences virulence in swine","volume":"81","author":"Risatti","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.01.038_b0260","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.virol.2011.08.025","article-title":"Effects of glycosylation on antigenicity and immunogenicity of classical swine fever virus envelope proteins","volume":"420","author":"Gavrilov","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2023.01.038_b0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-021-01507-1","article-title":"Generation and immunogenicity analysis of recombinant classical swine fever virus glycoprotein E2 and Erns expressed in baculovirus expression system","volume":"18","author":"Wei","year":"2021","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2023.01.038_b0270","doi-asserted-by":"crossref","first-page":"10457","DOI":"10.1007\/s00253-018-9430-6","article-title":"Glycosylation control technologies for recombinant therapeutic proteins","volume":"102","author":"Gupta","year":"2018","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2023.01.038_b0275","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0378-1135(99)00003-6","article-title":"Efficacy and stability of a subunit vaccine based on glycoprotein E2 of classical swine fever virus","volume":"66","author":"Bouma","year":"1999","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.vaccine.2023.01.038_b0280","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13568-019-0864-8","article-title":"Plasticity of the HEK-293 cells, related to the culture media, as platform to produce a subunit vaccine against classical swine fever virus","volume":"9","author":"Lorenzo","year":"2019","journal-title":"AMB Exp"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23000592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23000592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:23:39Z","timestamp":1759404219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23000592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0264410X23000592"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.038","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of stable HEK293T cell pools expressing CSFV E2 protein: A potential antigen expression platform","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}